# A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

> **NCT06492304** · PHASE1,PHASE2 · COMPLETED · sponsor: **CRISPR Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- T Cell Lymphoma
- B Cell Lymphoma
- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CTX131

## Key facts

- **NCT ID:** NCT06492304
- **Lead sponsor:** CRISPR Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-13
- **Primary completion:** 2026-03-11
- **Final completion:** 2026-03-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492304, "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06492304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*